These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34127581)

  • 1. Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.
    Granger LA; Huettner I; Debeljak F; Kaleebu P; Schechter M; Tambussi G; Weber J; Miro JM; Phillips R; Babiker A; Cooper DA; Fisher M; Ramjee G; Fidler S; Frater J; Fox J; Doores KJ
    AIDS; 2021 Nov; 35(13):2073-2084. PubMed ID: 34127581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
    Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR
    J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
    Sacks D; Wiehe K; Morris L; Moore PL
    J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
    Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
    PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.
    Doores KJ; Kong L; Krumm SA; Le KM; Sok D; Laserson U; Garces F; Poignard P; Wilson IA; Burton DR
    J Virol; 2015 Jan; 89(2):1105-18. PubMed ID: 25378488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
    Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
    Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.
    Bibollet-Ruche F; Russell RM; Ding W; Liu W; Li Y; Wagh K; Wrapp D; Habib R; Skelly AN; Roark RS; Sherrill-Mix S; Wang S; Rando J; Lindemuth E; Cruickshank K; Park Y; Baum R; Carey JW; Connell AJ; Li H; Giorgi EE; Song GS; Ding S; Finzi A; Newman A; Hernandez GE; Machiele E; Cain DW; Mansouri K; Lewis MG; Montefiori DC; Wiehe KJ; Alam SM; Teng IT; Kwong PD; Andrabi R; Verkoczy L; Burton DR; Korber BT; Saunders KO; Haynes BF; Edwards RJ; Shaw GM; Hahn BH
    mBio; 2023 Feb; 14(1):e0337022. PubMed ID: 36629414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
    Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
    Front Immunol; 2021; 12():670561. PubMed ID: 35003053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.
    Mishra N; Makhdoomi MA; Sharma S; Kumar S; Dobhal A; Kumar D; Chawla H; Singh R; Kanga U; Das BK; Lodha R; Kabra SK; Luthra K
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31217240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies.
    Wagh K; Hahn BH; Korber B
    Curr Opin HIV AIDS; 2020 Sep; 15(5):267-274. PubMed ID: 32675574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.